Mutational Spectrum and Prognosis Analysis of Young Patients with Diffuse Large B-Cell Lymphoma Based on Next-Generation Sequencing.
10.19746/j.cnki.issn.1009-2137.2023.02.014
- Author:
Li-Yang LYU
1
;
Yu-Ling NIE
1
;
Abulaiti RENAGULI
1
;
Xiao-Long QI
1
;
Abuduer MUHEBAIER
1
;
Shun-Sheng ZHAI
1
;
Li AN
1
;
Min MAO
1
;
Yan LI
2
Author Information
1. Department of Hematology, The People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001， Xinjiang Uygur Autonomous Region, China.
2. Department of Hematology, The People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001， Xinjiang Uygur Autonomous Region, China .E-mail:liyan232917@139.com.
- Publication Type:Journal Article
- Keywords:
gene mutation;
prognosis;
young;
diffuse large B-cell lymphoma;
next-generation sequencing
- MeSH:
Humans;
Retrospective Studies;
Prognosis;
Lymphoma, Large B-Cell, Diffuse/genetics*;
Biomarkers;
Mutation;
High-Throughput Nucleotide Sequencing
- From:
Journal of Experimental Hematology
2023;31(2):403-410
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the mutational spectrum in young patients with diffuse large B-cell lymphoma (DLBCL) based on next generation sequencing (NGS), and to provide a basis for in-depth understanding of the molecular biological characteristics and accurate prognosis of young DLBCL.
METHODS:From March 2009 to March 2021, 68 young DLBCL patients with complete initial diagnosis data from the Department of Hematology, The People's Hospital Xinjiang Uygur Autonomous Region were retrospectively analyzed, and their paraffin-embedded tissues were subjected to targeted sequencing analysis by NGS technology (including 475 Target genes), and the differences in gene mutation profiles and signaling pathways between high-risk patients with aaIPI ≥2 and low-intermediate risk patients with aaIPI <2 were compared.
RESULTS:A total of 44 high-frequency mutation genes were detected in 68 young DLBCL patients. By comparing the high-frequency mutation genes in aaIPI high-risk group and low-intermediate risk group, it was found that CARD11 mutation in aaIPI high-risk group was significantly higher than that in low-intermediate risk group (P =0.002), while MGA mutation (P =0.037) only appeared in the aaIPI high-risk group, and SPEN mutation (P =0.004) only appeared in the aaIPI low-intermediate risk group. The high-frequency mutation genes and clinical indicators of the aaIPI high-risk group were included in the survival analysis, and the results showed that TP53 (P =0.009, P =0.027), POU2AF1 (P =0.003, P =0.006) and CCND3 (P =0.040, P =0.014) genes mutations were associated with worse PFS and OS, while B2M was associated with better PFS (P =0.014) and OS (P =0.013). Multivariate COX regression analysis showed that the TP53, POU2AF1 and CCND3 were independent risk factors for PFS（P ＝0.021，P =0.005，P =0.020） and OS（P ＝0.042，P =0.010，P =0.013）.
CONCLUSION:The aaIPI staging combination with molecular biology markers is more conducive to accurately judging the prognosis of young DLBCL patients. TP53, POU2AF1 and CCND3 mutations predict worse survival in the patients with the aaIPI high-risk group.
